Trial Profile
Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes Following Peripheral Nerve Injury
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications Peripheral nerve injuries
- Focus Therapeutic Use
- 08 Aug 2023 Status changed from active, no longer recruiting to recruiting.
- 06 Dec 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 06 Dec 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.